Compare HITI & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HITI | CNTN |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 12 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.6M | 185.3M |
| IPO Year | 2021 | 2022 |
| Metric | HITI | CNTN |
|---|---|---|
| Price | $2.43 | $3.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.13 | N/A |
| AVG Volume (30 Days) | 406.7K | ★ 490.6K |
| Earning Date | 06-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.73 | N/A |
| Revenue Next Year | $12.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $2.89 |
| 52 Week High | $4.06 | $5.27 |
| Indicator | HITI | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 57.44 |
| Support Level | $2.36 | $3.02 |
| Resistance Level | $2.69 | $3.76 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 34.00 | 76.06 |
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.